Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Methods A systematic search was conducted using the Medline® and Embase® databases
up to 30 June 2017 employing specific medical subject heading terms. Additionally, the …

Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …

Many of the best-selling 'blockbuster'biological medicinal products are, or will soon be,
facing competition from similar biological medicinal products (biosimilars) in the EU …

Background The efficacy, safety and immunogenicity risk of switching between an originator
biologic and a biosimilar or from one biosimilar to another are of potential concern …

Introduction: The nocebo effect is defined as a negative effect of a pharmacological or non-
pharmacological medical treatment that is induced by patients' expectations, and that is …

BACKGROUND: Several authors have hypothesized that adverse drug events (ADEs) upon
switching from reference biologics to biosimilar products are related to the nocebo effect …

Abstract Background & Aims Crohn's disease (CD) is a lifelong illness with substantial
morbidity, although new therapies and treatment paradigms have been developed. We …

Abstract Purpose of Review Biosimilars of the reference biologic therapeutics infliximab,
etanercept, adalimumab, and rituximab are entering the market. Clinical and real-world data …

In recent years, marketing of highly innovative and costly biologics improved the
management of high-burden diseases such as autoimmune diseases, cancers, and chronic …